Bank of America’s Stemline Therapeutics, Inc. STML Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-29,289
Closed -$142K 7338
2020
Q1
$142K Buy
29,289
+7,774
+36% +$50.4K ﹤0.01% 5313
2019
Q4
$229K Sell
21,515
-6,514
-23% -$64.7K ﹤0.01% 5558
2019
Q3
$292K Sell
28,029
-42,666
-60% -$558K ﹤0.01% 5426
2019
Q2
$1.08M Sell
70,695
-79,882
-53% -$1.16M ﹤0.01% 4507
2019
Q1
$1.94M Buy
150,577
+139,908
+1,311% +$1.58M ﹤0.01% 4017
2018
Q4
$101K Buy
10,669
+3,866
+57% +$50.1K ﹤0.01% 5914
2018
Q3
$112K Sell
6,803
-13,745
-67% -$220K ﹤0.01% 5820
2018
Q2
$329K Buy
20,548
+10,159
+98% +$181K ﹤0.01% 5129
2018
Q1
$158K Buy
10,389
+3,730
+56% +$58.1K ﹤0.01% 5502
2017
Q4
$103K Buy
6,659
+2,383
+56% +$31.9K ﹤0.01% 5725
2017
Q3
$47K Buy
4,276
+1,039
+32% +$9.77K ﹤0.01% 5974
2017
Q2
$30K Sell
3,237
-2,709
-46% -$22.6K ﹤0.01% 6092
2017
Q1
$51K Buy
5,946
+1,399
+31% +$12.8K ﹤0.01% 5923
2016
Q4
$49K Buy
4,547
+1,588
+54% +$19.2K ﹤0.01% 5944
2016
Q3
$33K Buy
2,959
+382
+15% +$3.11K ﹤0.01% 5910
2016
Q2
$18K Sell
2,577
-20,488
-89% -$129K ﹤0.01% 6299
2016
Q1
$107K Buy
23,065
+1,149
+5% +$5.61K ﹤0.01% 5455
2015
Q4
$138K Buy
21,916
+19,779
+926% +$161K ﹤0.01% 5583
2015
Q3
$19K Buy
2,137
+100
+5% +$1.05K ﹤0.01% 6328
2015
Q2
$24K Buy
2,037
+367
+22% +$5.1K ﹤0.01% 6274
2015
Q1
$24K Sell
1,670
-1,224
-42% -$18.7K ﹤0.01% 5979
2014
Q4
$49K Buy
2,894
+2,602
+891% +$37.5K ﹤0.01% 6363
2014
Q3
$3K Sell
292
-10,208
-97% -$126K ﹤0.01% 7718
2014
Q2
$154K Buy
10,500
+10,480
+52,400% +$161K ﹤0.01% 5783
2014
Q1
$0 Sell
20
-6,409
-100% -$156K ﹤0.01% 8242
2013
Q4
$126K Buy
6,429
+5,664
+740% +$151K ﹤0.01% 5960
2013
Q3
$35K Sell
765
-11,184
-94% -$365K ﹤0.01% 6631
2013
Q2
$285K Buy
+11,949
New +$190K ﹤0.01% 5273

Bank of America's STML Position: Q2 2020 in Review

Bank of America sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 29,289 shares — an estimated $142K sold.

Bank of America first reported a position in STML in Q2 2013 and held it in 28 quarters. The position peaked at $1.94M in Q1 2019. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.

  • Bank of America reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Bank of America sold 29,289 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $142K.
  • Bank of America first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 28 quarters.
  • Bank of America's Stemline Therapeutics, Inc. position peaked at $1.94M in Q1 2019.
  • 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.

Based on Bank of America's 13F filing for Q2 2020, filed 14 Aug 2020.